Literature DB >> 25724648

Specific amyloid β clearance by a catalytic antibody construct.

Stephanie A Planque1, Yasuhiro Nishiyama1, Sari Sonoda1, Yan Lin2, Hiroaki Taguchi1, Mariko Hara1, Steven Kolodziej1, Yukie Mitsuda1, Veronica Gonzalez2, Hameetha B R Sait2, Ken-ichiro Fukuchi3, Richard J Massey4, Robert P Friedland5, Brian O'Nuallain6, Einar M Sigurdsson7, Sudhir Paul8.   

Abstract

Classical immunization methods do not generate catalytic antibodies (catabodies), but recent findings suggest that the innate antibody repertoire is a rich catabody source. We describe the specificity and amyloid β (Aβ)-clearing effect of a catabody construct engineered from innate immunity principles. The catabody recognized the Aβ C terminus noncovalently and hydrolyzed Aβ rapidly, with no reactivity to the Aβ precursor protein, transthyretin amyloid aggregates, or irrelevant proteins containing the catabody-sensitive Aβ dipeptide unit. The catabody dissolved preformed Aβ aggregates and inhibited Aβ aggregation more potently than an Aβ-binding IgG. Intravenous catabody treatment reduced brain Aβ deposits in a mouse Alzheimer disease model without inducing microgliosis or microhemorrhages. Specific Aβ hydrolysis appears to be an innate immune function that could be applied for therapeutic Aβ removal.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Alzheimer Disease; Amyloid-β (Abeta); Antibody Engineering; Catalytic Antibodies; Enzyme Catalysis; Immunotherapy; Innate Immunity; Light Chain Variable Domain; Neurotoxicity

Mesh:

Substances:

Year:  2015        PMID: 25724648      PMCID: PMC4400338          DOI: 10.1074/jbc.M115.641738

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.

Authors:  Hiroaki Fukumoto; Takahiko Tokuda; Takashi Kasai; Noriko Ishigami; Hiroya Hidaka; Masaki Kondo; David Allsop; Masanori Nakagawa
Journal:  FASEB J       Date:  2010-03-25       Impact factor: 5.191

2.  Nature and nurture of catalytic antibodies.

Authors:  Sudhir Paul; Stephanie A Planque; Yasuhiro Nishiyama; Carl V Hanson; Richard J Massey
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

3.  Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells.

Authors:  S Efthimiopoulos; D Vassilacopoulou; J A Ripellino; N Tezapsidis; N K Robakis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

4.  An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

Authors:  Oskar Adolfsson; Maria Pihlgren; Nicolas Toni; Yvan Varisco; Anna Lucia Buccarello; Katia Antoniello; Sophie Lohmann; Kasia Piorkowska; Valerie Gafner; Jasvinder K Atwal; Janice Maloney; Mark Chen; Alvin Gogineni; Robby M Weimer; Deborah L Mortensen; Michel Friesenhahn; Carole Ho; Robert Paul; Andrea Pfeifer; Andreas Muhs; Ryan J Watts
Journal:  J Neurosci       Date:  2012-07-11       Impact factor: 6.167

5.  The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol.

Authors:  Paul J Barrett; Yuanli Song; Wade D Van Horn; Eric J Hustedt; Johanna M Schafer; Arina Hadziselimovic; Andrew J Beel; Charles R Sanders
Journal:  Science       Date:  2012-06-01       Impact factor: 47.728

Review 6.  Review: sporadic cerebral amyloid angiopathy.

Authors:  J Attems; K Jellinger; D R Thal; W Van Nostrand
Journal:  Neuropathol Appl Neurobiol       Date:  2011-02       Impact factor: 8.090

7.  Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer.

Authors:  Fancy C Thomas; Kunal Taskar; Vinay Rudraraju; Satyanarayana Goda; Helen R Thorsheim; Julie A Gaasch; Rajendar K Mittapalli; Diane Palmieri; Patricia S Steeg; Paul R Lockman; Quentin R Smith
Journal:  Pharm Res       Date:  2009-09-23       Impact factor: 4.200

Review 8.  Pharmacokinetics and biodistribution of genetically-engineered antibodies.

Authors:  D Colcher; G Pavlinkova; G Beresford; B J Booth; A Choudhury; S K Batra
Journal:  Q J Nucl Med       Date:  1998-12

Review 9.  The functional neurophysiology of the amyloid precursor protein (APP) processing pathway.

Authors:  A D Randall; J Witton; C Booth; A Hynes-Allen; J T Brown
Journal:  Neuropharmacology       Date:  2010-02-16       Impact factor: 5.250

10.  Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.

Authors:  Reisa Sperling; Stephen Salloway; David J Brooks; Donatella Tampieri; Jerome Barakos; Nick C Fox; Murray Raskind; Marwan Sabbagh; Lawrence S Honig; Anton P Porsteinsson; Ivan Lieberburg; H Michael Arrighi; Kristen A Morris; Yuan Lu; Enchi Liu; Keith M Gregg; H Robert Brashear; Gene G Kinney; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2012-02-03       Impact factor: 44.182

View more
  9 in total

Review 1.  Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.

Authors:  Shu-Hui Xin; Lin Tan; Xipeng Cao; Jin-Tai Yu; Lan Tan
Journal:  Neurotox Res       Date:  2018-04-07       Impact factor: 3.911

Review 2.  Antibody-Mediated Catalysis in Infection and Immunity.

Authors:  Anthony Bowen; Maggie Wear; Arturo Casadevall
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

3.  Catalytic antibodies in patients with systemic lupus erythematosus.

Authors:  Vandana Pradhan; Pallavi Pandit; Prathamesh Surve; Maxime Lecerf; Anjali Rajadhyaksha; Milind Nadkar; Prasad V Khadilkar; Durga A Chougule; Aalaap A Naigaonkar; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Kanjaksha Ghosh; Srini V Kaveri
Journal:  Eur J Rheumatol       Date:  2018-08-07

Review 4.  Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications.

Authors:  Jianming Wu; Ling Li
Journal:  J Biomed Res       Date:  2016-01-02

5.  Anti-Double-Stranded DNA IgG Participates in Renal Fibrosis through Suppressing the Suppressor of Cytokine Signaling 1 Signals.

Authors:  Ping Wang; Jie Yang; Fang Tong; Zhaoyang Duan; Xingyin Liu; Linlin Xia; Ke Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

Review 6.  Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives.

Authors:  Hilal Ahmed Parray; Shivangi Shukla; Sweety Samal; Tripti Shrivastava; Shubbir Ahmed; Chandresh Sharma; Rajesh Kumar
Journal:  Int Immunopharmacol       Date:  2020-05-27       Impact factor: 4.932

7.  Experimental Autoimmune Encephalomyelitis of Mice: Enzymatic Cross Site-Specific Hydrolysis of H4 Histone by IgGs against Histones and Myelin Basic Protein.

Authors:  Andrey E Urusov; Kseniya S Aulova; Pavel S Dmitrenok; Valentina N Buneva; Georgy A Nevinsky
Journal:  Int J Mol Sci       Date:  2022-08-16       Impact factor: 6.208

Review 8.  Catalytic Antibodies: Design, Expression, and Their Applications in Medicine.

Authors:  Daqun Zhao; Jie Chen; Xiaoyue Hu; Shujun Zhang
Journal:  Appl Biochem Biotechnol       Date:  2022-10-12       Impact factor: 3.094

Review 9.  Recombinant Antibody Fragments for Neurodegenerative Diseases.

Authors:  Karen Manoutcharian; Roxanna Perez-Garmendia; Goar Gevorkian
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.